PCI Biotech Reports Strong First Half Results for 2024
Oslo, Norway – PCI Biotech (OSE: PCIB) is pleased to share its interim results for the first half of 2024. The company has made notable progress in its operational framework, highlighting developments that emphasize its commitment to advancing its photochemical technology platform. This report summarizes the key highlights from this period, reflecting the company’s focus on scalability and the advantages of its proprietary technologies.
Operations Overview
In 2024, PCI Biotech has set ambitious goals aimed at showcasing the scalability and efficiency of its photochemical-based technology (PCL), particularly in the manufacturing of viral vectors. This aligns with the company’s strategic vision to leverage innovative solutions that enhance biopharmaceutical production.
Field Testing Results
In the first quarter of 2024, results from collaborative field testing with a European partner confirmed the promising advantages of using photochemical methods in the production of viral vectors, especially adeno-associated viruses (AAV). These findings represent significant milestones in assessing the scalability of the technology and pave the way for further development phases.
Development Initiatives
To advance the commercialization of PCL technology, PCI Biotech is actively partnering with a respected service provider in the Advanced Therapy Medicinal Products (ATMP) sector. This collaboration focuses on adapting the technology for use in mini benchtop bioreactors, which serve as representative models for larger manufacturing processes.
Mini Benchtop Bioreactor Insights
Initial trials with mini benchtop bioreactors have shown promising compatibility of PCL technology with commonly employed downstream processes. While these results suggest potential enhancements in manufacturing efficiency, further research is required to fully understand the benefits PCL can bring to the biopharmaceutical industry. The team is committed to advancing these studies to achieve their development goals for 2024.
Corporate Financial Position
As of the end of June 2024, PCI Biotech's cash reserves stood at NOK 30.5 million, positioning the company to maintain its operations into the second half of 2025 under its current strategic plans. This financial flexibility is crucial for continuing to demonstrate the commercial potential of its technology platform.
CEO Insights
Ronny Skuggedal, CEO of PCI Biotech, commented on the company’s positive momentum: “After receiving encouraging feedback from early field testing at the beginning of this year, we accelerated our development efforts by successfully advancing the PCL technology to a reputable service provider for scale-up applications. The results from the initial mini benchtop bioreactor trials have provided essential insights into the technology’s compatibility with standard manufacturing processes, which is a key factor in our ongoing business development discussions.”
Upcoming Events
A live webcast in Norwegian is scheduled for today from 08:30 am to 09:00 am CEST. Participants are invited to join the session, which will include a Q&A segment following the presentation. This session aims to provide in-depth insights into the interim results and operational strategies.
About PCI Biotech
PCI Biotech is a biopharmaceutical innovator dedicated to developing and commercializing transformative therapies through its unique photochemical technology platform, which originates from pioneering research at Oslo University Hospital. The company is focusing on two key areas: (1) Photochemical Lysis (PCL), which enhances yield and purity in viral vector manufacturing through light-triggered cell lysis, and (2) Photochemical Internalization (PCI), which enables light-triggered endosomal release, unlocking various therapeutic modalities.
Contact Information
For more information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
Frequently Asked Questions
What are the key highlights of PCI Biotech's first half 2024 results?
The key highlights include advancements in the scalability of PCL technology and positive field testing results indicating its potential in viral vector manufacturing.
How is PCI Biotech progressing with its PCL technology?
PCI Biotech is currently collaborating with an ATMP service provider to transition PCL technology into mini benchtop bioreactors, showing promising compatibility with standard processes.
What is the financial status of PCI Biotech?
As of June 2024, PCI Biotech reported cash reserves of NOK 30.5 million, which is expected to support operations through 2025.
Who is the CEO of PCI Biotech?
Ronny Skuggedal serves as the CEO and CFO of PCI Biotech, overseeing the company's strategic directions and operational advancements.
Where can I find more information about PCI Biotech?
Additional information can be found on PCI Biotech's official website, www.pcibiotech.com, which contains detailed reports and presentations.
